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Use of combined oral contraceptives and risk of venous 
thromboembolism: nested case-control studies using the 
QResearch and CPRD databases
Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox 
ABSTRACT
ObjeCtive
To investigate the association between use of 
combined oral contraceptives and risk of venous 
thromboembolism, taking the type of progestogen into 
account.
Design
Two nested case-control studies.
setting
General practices in the United Kingdom contributing 
to the Clinical Practice Research Datalink (CPRD; 618 
practices) and QResearch primary care database (722 
practices).
PartiCiPants
Women aged 15-49 years with a first diagnosis of 
venous thromboembolism in 2001-13, each matched 
with up to five controls by age, practice, and calendar 
year.
Main OutCOMe Measures
Odds ratios for incident venous thromboembolism and 
use of combined oral contraceptives in the previous 
year, adjusted for smoking status, alcohol 
consumption, ethnic group, body mass index, 
comorbidities, and other contraceptive drugs. Results 
were combined across the two datasets.
results
5062 cases of venous thromboembolism from CPRD 
and 5500 from QResearch were analysed. Current 
exposure to any combined oral contraceptive was 
associated with an increased risk of venous 
thromboembolism (adjusted odds ratio 2.97, 95% 
confidence interval 2.78 to 3.17) compared with no 
exposure in the previous year. Corresponding risks 
associated with current exposure to desogestrel (4.28, 
3.66 to 5.01), gestodene (3.64, 3.00 to 4.43), 
drospirenone (4.12, 3.43 to 4.96), and cyproterone 
(4.27, 3.57 to 5.11) were significantly higher than those 
for second generation contraceptives levonorgestrel 
(2.38, 2.18 to 2.59) and norethisterone (2.56, 2.15 to 
3.06), and for norgestimate (2.53, 2.17 to 2.96). The 
number of extra cases of venous thromboembolism 
per year per 10 000 treated women was lowest for 
levonorgestrel (6, 95% confidence interval 5 to 7) and 
norgestimate (6, 5 to 8), and highest for desogestrel 
(14, 11 to 17) and cyproterone (14, 11 to 17).
COnClusiOns
In these population based, case-control studies using 
two large primary care databases, risks of venous 
thromboembolism associated with combined oral 
contraceptives were, with the exception of 
norgestimate, higher for newer drug preparations than 
for second generation drugs.
Introduction
About 9% of women of reproductive age worldwide 
use oral contraceptives. This percentage rises to 18% 
of women in developed countries and 28% of women 
in the United Kingdom.1 Combined oral contraceptives 
form a substantial proportion of these, particularly in 
more developed nations. Although combined oral con-
traceptives are generally effective in preventing preg-
nancy, they have measurable side effects such as 
venous thromboembolism (VTE). VTE is important, 
not only because of the prolonged time over which 
women might be exposed to such contraceptives, but 
also because VTEs are potentially avoidable and can 
be fatal. 
Previous studies have shown varying risks for differ-
ent types of oral contraceptives (such as third genera-
tion pills compared with first or second generation 
pills), but such studies were done some years ago,2-6 
and tended not to include new preparations containing 
drospirenone. Also, previous studies have generally 
had insufficient power to analyse the risks for more 
recent formulations7-10  such as norgestimate. Few stud-
ies—only four of those referenced here9 11-13 —have 
included any detailed analyses of dosage and, of these, 
only Lidegaard and colleagues12  have covered a full 
range of prescribed drugs. Some studies did not control 
for all potential confounders (such as body mass index 
or smoking),12  while others analysed only  healthy 
users.4 11 14  Different methodological approaches in 
studies have also made it difficult to compare and 
WhAT IS AlReAdy knoWn on ThIS TopIC
Oral contraceptive pills are known to be associated with an increased risk of 
thromboembolism (VTE)
Despite comparing third generation contraceptive pills with first and second 
generation pills, previous studies have had insufficient power to quantify VTE risk 
with individual drugs, particularly for new or less commonly used preparations such 
as drospirenone or norgestimate
WhAT ThIS STudy AddS
This study, based on national population and prescribing practices in the UK, has 
sufficient power to provide reliable comparative findings for different formulations 
of combined oral contraceptives; its findings are comparable to those based on a 
Danish national cohort study
Preparations containing gestodene, desogestrel, drospirenone, and cyproterone 
were associated with significantly higher risks of VTE than preparations containing 
either levonorgestrel or norgestimate
The number of extra VTE cases per year per 10 000 treated women was lowest for 
levonorgestrel and norgestimate, and highest for desogestrel and cyproterone
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 combine the results.15  Therefore, although the 
increased VTE risk associated with combined oral con-
traceptive drugs is established, the relative risks associ-
ated with different combinations remain inconclusive, 
especially for newer formulations.16  17
The UK has some of the largest sources of routinely 
collected data in the world, with longitudinal primary 
care records spanning up to 25 years and linked to sec-
ondary care data and mortality records. These data-
bases cover many millions of patients, include data 
both on exposure and outcomes, and therefore are rep-
resentative of the setting in which drugs are used. This 
makes the databases ideally suited to large scale safety 
studies of commonly used drugs.18  19 In this study, we 
have used the two largest of these databases, QResearch 
(www.qresearch.org) and Clinical Practice Research 
Datalink (CPRD, www.cprd.com). Both have been used 
for earlier studies of associations between drug pre-
scribing and VTE risks.4  5 10 14 20 21
Our objective was to quantify the associations 
between use of combined oral contraceptives and risk 
of VTE, adjusting for comorbidities and other available 
confounding factors. In particular, we were interested 
to analyse risks associated with newer or less used 
preparations such as drospirenone or norgestimate, 
quantify risks associated with various types of pro-
gestogen, and analyse the effect of different doses of 
oestrogen on VTE risks. To make the study more compa-
rable with previous studies, we also replicated analyses 
for different subgroups by age and health status and for 
VTE cases with anticoagulation prescriptions.
Methods
study design
The protocol for this study has already been pub-
lished.15  We undertook two similar studies using the 
CPRD (January 2014 version; 618 UK general practices) 
and QResearch database (version 38; 722 general prac-
tices) to quantify the association between prescribing of 
combined oral contraceptives and risk of incident VTE. 
We identified open cohorts of all women who had no 
records of VTE before the study, were aged 15-49 years, 
and were registered with the study practices between 
2001 and 2013. Within each cohort, we designed two 
nested case-control studies with incident cases of VTE 
during the study period. This design was chosen as the 
most practicable, because it allowed us to work within 
the maximum extraction capabilities of the databases 
without losing any of the available cases—and therefore 
not compromising either the power of the study or the 
generalisability of the findings.22
The methods used in the study followed exactly those 
of the published protocol, with one difference related to 
the use of linked data. With respect to case identifica-
tion, the protocol specified that “the main analysis will 
be run on all cases with VTE identified from the general 
practice data.” QResearch is, however, closely linked at 
the individual patient level to hospital admissions data, 
and mortality records from the UK Office for National 
Statistics (ONS, www.ons.gov.uk/; complete for 99.8% 
of patients in QResearch, 99.9% of ONS mortality 
records, and 98% of hospital admissions records)23  24. 
So we identified VTE cases if, in QResearch, there was a 
relevant clinical code in the GP record, linked hospital 
record, or linked mortality record (web table 1), using 
the earliest recorded date on any of the three sources as 
the index date. For CPRD, however, not all practices 
were linked to these external data, so we could use only 
general practice records to identify VTE cases in CPRD.
For both databases, we matched each case to up to 
five controls by year of birth and from the same practice 
using incidence density sampling. Each control was 
allocated an index date, which was the date of first VTE 
diagnosis for the matched case. Eligible women had to 
have been registered with their practice for at least one 
year before the index date.
Because records of prescriptions for anticoagulant 
therapy (BNF 2.8.2) might indicate a previous VTE epi-
sode that was not recorded, cases with such records six 
or more weeks before the index date and controls with 
such records at any time before the index date were 
excluded from the analysis. We also excluded women if 
they had conditions such as oophorectomy, hysterec-
tomy, and sterilisation, which normally preclude use of 
combined oral contraceptives. Women identified as 
pregnant or in the first three months after delivery at the 
index date were excluded, because they were less likely 
to be users of combined oral contraceptives and have an 
increased risk of VTE.25 Cases or controls with conflict-
ing prescriptions—two or more prescriptions for differ-
ent combined oral contraceptives issued on the same 
date for the month before the index date—were also 
removed from the analysis.
exposure to oral contraceptive drugs
Exposure to hormonal contraceptive drugs was based 
on prescription information in the last year before the 
index date. The main focus of the study was on indi-
vidual combined oral contraceptives, which included 
all the most commonly used preparations in the UK: 
norethisterone, levonorgestrel, norgestimate, desoge-
strel, gestodene, and drospirenone (BNF 7.3.1). We 
included cyproterone, a hormonal treatment for acne, 
because it is also used as an oral contraceptive owing 
to its progestogen-like effect on the release of testos-
terone by the ovaries (BNF 13.6.2). For confounder 
control, the analysis included oral progestogen only 
contraceptives (BNF 7.3.2) and non-oral hormonal 
contraceptives (BNF 7.3.1 and BNF 7.3.2: implants, 
injections, transdermal patches, intrauterine and vag-
inal devices).
We investigated the recency of use by calculating the 
gap in days between the estimated date for the last use 
of a combined oral contraceptive and the index date, 
and categorising it as follows: used at index date or last 
use 1-28 days before the index date (current use); last 
use 29-365 days before the index date (past use); or no 
use in the last year before the index date. If a woman 
was exposed to more than one combined oral contra-
ceptive in the last 28 days, only the latest time used was 
considered, but an indicator that she had switched type 
of oral contraceptive in the last 28 days was included in 
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the analysis. No use in the last year was a reference cat-
egory for all analyses unless otherwise stated.
We included the category of past use in the analysis 
to allow for women having an increased VTE risk asso-
ciated with previous drug use, either because of a very 
recent cessation of exposure close to the start of the cur-
rent use period or because of a delayed start of drug use 
from a previous prescription, such that some women 
classified as past users were actually current users. This 
approach was used only to approximate short term 
residual and misclassification effects, and should not 
be interpreted as a measure of long term residual risk. 
To emphasise this, we have reported odds ratios for past 
users only in the web tables.
Use of other hormonal contraceptives (oral pro-
gestogen only and non-oral hormonal treatments) 
was similarly categorised into current and past expo-
sure and added to the analysis as confounders. We 
aggregated the data for combined and progestogen 
only non-oral contraceptives, because the numbers of 
current users for combined non-oral contraceptives 
were low (13 cases and 24 controls in CPRD, 11 cases 
and 14 controls in QResearch) and lacked power for 
separate analysis.
Because VTE risk is likely to be highest in the first 
three months of oral contraceptive use,26 we estimated 
the effect of duration of exposure on current users. We 
assessed exposure duration by calculating the number 
of days of exposure within the previous year. If the gap 
between the end of one prescription and the start of the 
next was 30 days or less, we considered exposure was 
continuous and combined the durations of the prescrip-
tions. If a gap was longer than 30 days, only the latest 
period of exposure was considered. 
Length of exposure duration was based on a period of 
84 days, the most common length of a contraceptive 
prescription and also close to the end of the period of 
highest VTE risk associated with contraceptive use in 
other studies.7  9 We classified duration as short term 
(≤84 days) and long term (>84 days), and combined it 
with recency of use into the following categories: short 
term current users (new users and restarters), long term 
current users (prevalent users), past use, and no use in 
the previous year.
In our samples, three contraceptives—norethis-
terone, desogestrel and gestodene—were prescribed in 
combinations having different doses of oestrogen. 
Owing to evidence of associations between higher VTE 
risks and higher doses of oestrogen12, we undertook a 
further analysis of current users and categorised sepa-
rately the oestrogen dose for these preparations (low 
dose (20 µg), normal dose (30-40 µg)), based on their 
most recent prescriptions before the index date. There 
was only one preparation with a high oestrogen dose 
(50 µg), which was combined with norethisterone. 
However, since there were only seven current users with 
this high dose preparation across both databases (one 
case and one control in CPRD, one case and four con-
trols in QResearch), we included these women in the 
normal dose category. For all other drugs, only normal 
dose combinations had been prescribed.
Confounding factors
We identified the conditions affecting risk of VTE from 
the UK’s health service guidelines related to VTE and 
hormonal contraceptives (web appendix 2).27 Since 
these conditions might affect the prescribing decisions 
of doctors, we decided to adjust for these in all analy-
ses. The chronic conditions for any patient had to be 
recorded before the index date in, to be included. These 
conditions were cancer, congestive cardiac failure, var-
icose veins, cardiovascular disease, rheumatoid arthri-
tis, systemic lupus erythematosus, chronic renal 
disease, asthma, chronic obstructive pulmonary dis-
ease, Crohn’s disease or ulcerative colitis, and coagula-
tion disturbances (Leiden factor V, protein C and S 
deficiencies). 
We also included traumatic events and events lead-
ing to immobilisation if recorded in the six months 
before the index date. These events included acute 
infections (upper and lower respiratory tract infections, 
urinary tract infections), surgery or leg/hip fracture, 
admission to hospital (excluding the previous 30 days 
before the index date). Non-idiopathic groups were 
formed from women with any of these chronic condi-
tions or events, and idiopathic groups from women 
without them.
Obesity and smoking are also mentioned as potential 
risk factors in the NHS guidelines, so we adjusted all 
analyses for body mass index as a continuous variable, 
and for smoking status as the following categories: cur-
rent smoker (light (1-9 cigarettes/day), medium (10-19), 
heavy (≥20); ex-smoker; non-smoker. We used values 
recorded at the closest date before the index date.
We included polycystic ovary syndrome as a con-
founder because it is treated with hormonal contracep-
tives and associated with an increased risk of VTE.28 
Other conditions treated with hormonal contraceptive 
prescriptions—acne, hirsutism, and menstrual disor-
ders—were initially considered as potential confound-
ers but their addition to analyses failed to change odds 
ratios for main exposures by more than 10%, so these 
were not included in the final study analyses.
Alcohol consumption has previously been consid-
ered as a confounder10  and, being a potentially import-
ant lifestyle factor available from primary care data,29 
was categorised and included in the analyses (light (≤2 
units/day), medium to heavy (≥3), ex-use or no use). We 
also adjusted for ethnic group (white or not recorded, 
Asian, black, or other), because women in ethnic 
minorities could have different patterns of contracep-
tive use30  and different VTE risks from the white popu-
lation.31
Social deprivation, which can be measured in the UK 
by the Townsend score, was not included as a con-
founder in the main analyses because it was not a sig-
nificant risk factor for VTE in a previous QResearch 
study.32 Furthermore, the CPRD had a large proportion 
of missing data for the Townsend score, so the inclu-
sion of social deprivation would result in a loss of sta-
tistical power in that analysis. However, during the 
peer review process, we decided to run an additional 
analysis on QResearch data including the Townsend 
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score as a confounder, because the Townsend data 
were almost complete (available for 99.8% of cases and 
controls). We have, therefore, run an additional analy-
sis on QResearch data including the Townsend score as 
a confounder.
statistical analysis
The analyses were run on each database separately. 
Crude incidence was calculated by dividing the number 
of cases with incident VTE by the number of person 
years in the cohorts. Data for oral contraceptive expo-
sure were only available for cases and matched controls 
rather than whole cohorts, which had higher propor-
tions of older women than the general population. 
Therefore, we estimated age standardised rates of expo-
sure to any oral contraceptives, using groups of controls 
before exclusions and directly standardising to the age 
profile for the UK general population in the relevant 
year based on data from the UK Office for National 
 Statistics.
We used conditional logistic regression to obtain 
odds ratios with 95% confidence intervals. The differ-
ences between exposures were assessed using Wald’s 
tests. To account for the log normal distribution for 
body mass index, we used the logarithm of body mass 
index for all analyses. Missing values for body mass 
index, smoking status, and alcohol consumption were 
imputed using chained equations.33  Ten imputed sets 
were generated, and the imputation model included 
age, outcome (case or control), index year, all con-
founding factors (including acne, hirsutism, and men-
strual disorders), exposure to progestogen only oral 
contraceptives, non-oral contraceptives (progestogen 
only and combined), and recency and duration of use 
for combined oral contraceptives. We combined the 
results from the imputed sets using Rubin’s rules.33
To facilitate comparison of our results with those 
from earlier studies, which had analysed the associa-
tions of exposure to combined oral contraceptives by 
reference to levonorgestrel, we reran the analyses com-
paring current exposure to each drug of interest with 
current exposure to levonorgestrel (in combination with 
a normal oestrogen dose (30-40µg), the only doses pre-
scribed in our data). Current exposures to levonorge-
strel and the drug of interest were replaced with a 
variable coded as exposure to the drug, no exposure to 
the drug, and exposure to levonorgestrel. Analyses were 
adjusted for past exposure to levonorgestrel and the 
drug of interest, exposure to other combined oral con-
traceptives, and confounding factors.
We ran three additional analyses to look at method-
ological issues and allow comparisons with other pub-
lished studies. Because results of diagnostic tests for 
VTE are not generally included in the primary care elec-
tronic records, some studies11  14 used subsequent anti-
coagulation therapy to confirm VTE diagnosis, 
including only patients treated as such despite possible 
under ascertainment of VTE cases. In our study, antico-
agulation records were available only for prescriptions 
in primary care, representing doctors’ initial responses 
to patients presenting with VTE symptoms rather than 
a more complete record of initial and subsequent treat-
ments. However, to facilitate comparison with these 
studies, we ran another analysis on VTE cases, sup-
ported with either prescriptions for anticoagulation 
therapy (BNF 2.8.2) or records of death within six weeks 
of the recorded date of VTE diagnosis. Links to individ-
ual mortality data from the ONS were available for all 
QResearch practices, so these were included in identifi-
cation of deaths due to VTE. This was not the case for 
CPRD practices, however, so identification of deaths for 
the CPRD analysis was derived solely from the general 
practitioner record.
To distinguish whether there are different associa-
tions in idiopathic cases compared with non-idiopathic 
cases, an additional stratified analysis was run on sub-
groups of cases and matched controls. In this analysis, 
idiopathic cases were first analysed with any idiopathic 
matched controls (that is, controls with none of the 
chronic conditions or events listed above). Then, only 
non-idiopathic cases were analysed with any non-idio-
pathic matched controls (that is, controls with one or 
more of the chronic conditions or events used to iden-
tify non-idiopathic cases). The third analysis was run 
on subgroups of younger (15-24 years) and older (25-49 
years) women, because younger women are more likely 
to use contraceptive clinics as a source of oral contra-
ceptives, potentially leading to a lack of recorded expo-
sure data for this group.30
In the protocol, we had proposed a sensitivity analy-
sis for practices linked to hospital admission data, 
where VTE cases would be identified not only from the 
practice records but also from hospital admissions 
data. For QResearch, because the selection process 
used linked data sources including hospital admis-
sions, this additional analysis became redundant. 
Instead, we ran a sensitivity analysis using QResearch 
cases identified only through general practice medical 
records and matched controls. For CPRD, we ran the 
proposed sensitivity analysis for data from the subset of 
practices linked to both hospital admission data and 
ONS mortality data, where data from all sources were 
used to identify VTE cases. VTE cases in hospital admis-
sion and ONS mortality data were identified by ICD-10 
codes (web table 1).
To increase the power of the study and obtain more 
precise estimates, we combined results from the two 
databases using a meta-analysis technique. Adjusted 
odds ratios from the conditional logistical regression 
analyses of the two datasets were pooled by use of a 
fixed effect model with inverse variance weights.34 We 
chose a fixed effect model because—apart from the nec-
essarily different approaches to identification of rele-
vant cases described above—the studies in CPRD and 
QResearch (which have similar sizes and similar meth-
ods of recording information) were comparable, using 
the same exclusion criteria, definitions of exposures 
and confounders, and the same models. In view of 
these similarities, differences in observed associations 
seemed most likely to derive from sampling variations, 
but we also ran a sensitivity analysis using a random 
effect model to allow for any heterogeneity.
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To estimate the magnitude of VTE risk associated 
with combined oral contraceptives, we calculated the 
numbers needed to harm per year by using the adjusted 
odds ratios derived from the combined analyses.35  The 
incidence for the unexposed female population could 
not be derived either from QResearch or CPRD because 
exposure details were not available for the whole 
cohorts. The rate was, therefore, derived from a Danish 
cohort12 taking into account the differences in study 
design. We based our calculations for numbers needed 
to harm on the adjusted odds ratios from the combined 
analyses for current use and the Danish study rates of 
4.18 per 10 000 women years for women aged 15-49 
years and 4.91 per 10 000 women years for those aged 
25-49 years. We also estimated the number of additional 
VTE cases expected per year per 10 000 treated women.
We used Stata version 13 for the analyses. All available 
cases were used from both QResearch and CPRD. A 1% 
level of statistical significance was used to account for 
multiple comparisons and 95% confidence intervals to 
enhance comparability with other studies. For clarity, 
only odds ratios from the combined analyses are pre-
sented and discussed, but the contributing odds ratios 
from CPRD and QResearch can be found in the tables.
Results 
We identified 7334 incident VTE cases from CPRD based 
on clinical Read codes recorded in the general practi-
tioner data, and 8211 incident VTE cases from QResearch 
within the study period, both with at least one year of 
medical records. Crude incidence of VTE cases per 
10 000 women years was 5.9 (95% confidence interval 5.7 
to 6.0) in CPRD and 6.1 (6.0 to 6.3) in QResearch. After 
matching cases to controls and removing ineligible par-
ticipants, the final analysis included 5062 (69%) VTE 
cases from CPRD matched to 19 638 controls, and 5500 
(67%) VTE cases from QResearch matched to 22 396 
 controls (fig 1). Of 5500 VTE cases from QResearch, 5088 
(93%) were identified from primary care records, and an 
additional 284 (5%) from hospital admission data and 
128 (2%) from ONS mortality data. For CPRD cases, 2917 
(58%) VTE events were recorded as deep vein thrombo-
sis only; 1626 (32%) as pulmonary embolism, with or 
without deep vein thrombosis; and 519 (10.3%) as other 
types of VTE; corresponding numbers for QResearch 
cases were 3156 (57%), 1613 (29%), and 731 (13%).
Proportions of cases and controls across the demo-
graphic measures and morbidities relevant to the study 
showed the similarities between database populations 
(table 1, web table 2). Median ages of women in the 
study were 38 years (interquartile range 30-44) for 
CPRD and 39 years (31-44) for QResearch. Current smok-
ing was more common in cases than controls (27% v 
21% for both databases), as was obesity (body mass 
index≥30; 30% v 17% for CPRD, 24% v 14% for QRe-
search). Proportions of women with established risk 
factors for VTE (that is, non-idiopathic cases and con-
trols) were similar for each database (47% cases and 
27% controls for CPRD, 47% and 26% for QResearch). 
About half of women with VTE in the study had antico-
agulation prescriptions or died within six weeks of the 
recorded diagnosis date (2454 and 79 cases, respec-
tively, or 50% overall in CPRD; 2749 and 207, or 54% 
overall in QResearch).
exposure, main analysis
Age standardised rates of exposure to any oral contra-
ceptive did not change over the study period (overall 
rates 29% in CPRD, 26% in QResearch). Use of levo-
norgestrel, the most common combined oral contracep-
tive, decreased during the study (from 15% to 11% in 
CPRD, and 13% to 10% in QResearch), whereas use of 
progestogen only oral contraceptives rose from 3% to 
7% (fig 2).
First episode of VTE 2001-13, cases and
controls with at least 1 year of data
Total (8211 cases; 40 952 controls)
First episode of VTE 2001-13, cases and
controls with at least 1 year of data
Total (7334 cases; 33 380 controls)
Remaining cases and controls
(5062, 69% cases; 19 638, 59% controls)
Excluded owing to previous anticoagulant therapy:
(146, 2% cases (>42 days before the diagnosis);
26, 0.1% controls (any time before index date))
Excluded owing to oophorectomy,
hysterectomy, and sterilisation:
(844, 14% cases; 2693, 9% controls)
Excluded owing to pregnancy:
(1266, 18% cases; 2379, 7% controls)
Excluded owing to conflicting prescriptions:
(6, 0.1% cases; 11, <0.1% controls)
Excluded owing to absence of a matched case or control:
(10, 0.2% cases; 8663, 31% controls)
Remaining cases and controls
(5500, 67% cases; 22 396, 55% controls)
Excluded owing to previous anticoagulant therapy:
(344, 4% cases (>42 days before the diagnosis);
155, 0.4% controls (any time before index date))
Excluded owing to oophorectomy,
hysterectomy, and sterilisation:
(864, 14% cases; 3315, 9% controls)
Excluded owing to pregnancy:
(1490, 19% cases; 4406, 11% controls)
Excluded owing to conflicting prescriptions:
(6, 0.1% cases; 10, <0.1% controls)
Excluded owing to absence of a matched case or control:
(7, 0.1% cases; 10 670, 32% controls)
CPRD QResearch
Fig 1 | Flow of included patients for CPrD and Qresearch analyses with proportions of excluded observations at each point 
of exclusion
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table 1 | baseline characteristics in cases and controls by database (CPrD or Qresearch)
CPrD Qresearch
Cases (n=5062) Controls (n=19 638) Cases (n=5500) Controls (n=22 396)
age band at index date
15-24 years 12.6 (636) 12.7 (2496) 9.0 (493) 9.5 (2135)
25-34 years 25.5 (1290) 23.8 (4666) 25.9 (1423) 25.0 (5589)
35-39 years 17.1 (867) 17.5 (3433) 18.0 (992) 17.7 (3957)
40-44 years 20.8 (1055) 21.9 (4292) 22.5 (1239) 23.3 (5219)
45-49 years 24.0 (1214) 24.2 (4751) 24.6 (1353) 24.5 (5496)
ethnic group
White 36.0 (1821) 33.4 (6561) 61.6 (3386) 57.6 (12 900)
Not recorded* 60.2 (3049) 62.4 (12 249) 29.5 (1620) 32.7 (7316)
Black 1.6 (79) 1.2 (237) 4.2 (233) 3.0 (680)
Asian 1.3 (68) 1.9 (375) 2.4 (134) 4.5 (1013)
Other 0.9 (45) 1.1 (216) 2.3 (127) 2.2 (487)
body mass index
15-24 34.6 (1753) 44.7 (8774) 34.6 (1903) 44.2 (9895)
25-29 22.6 (1142) 22.0 (4317) 21.9 (1202) 20.0 (4473)
≥30 30.3 (1534) 17.1 (3353) 24.2 (1331) 14.3 (3196)
Not recorded 12.5 (633) 16.3 (3194) 19.3 (1064) 21.6 (4832)
smoking status
Non-smoker 51.1 (2586) 54.2 (10 645) 43.5 (2392) 46.5 (10 410)
Ex-smoker 17.5 (884) 16.8 (3295) 23.3 (1280) 22.1 (4952)
Current light smoker 6.3 (319) 6.0 (1188) 14.4 (790) 12.1 (2703)
Current moderate smoker 14.4 (730) 11.2 (2194) 7.7 (424) 6.4 (1433)
Current heavy smoker 6.6 (334) 4.2 (828) 4.5 (248) 2.8 (621)
Not recorded 4.1 (209) 7.6 (1488) 6.7 (366) 10.2 (2277)
alcohol use
No use 20.0 (1014) 17.9 (3516) 22.2 (1220) 19.3 (4315)
Ex-use 6.0 (303) 4.4 (869) 6.7 (367) 5.3 (1177)
Light (≤2 units/day) 49.0 (2479) 50.5 (9921) 32.1 (1766) 32.9 (7365)
Moderate/heavy (≥3 units/day) 5.0 (254) 5.0 (986) 17.6 (970) 18.6 (4173)
Not recorded 20.0 (1012) 22.1 (4346) 21.4 (1177) 24.0 (5366)
non-idiopathic cases
Proportion (no) of cases or controls 47.0 (2380) 27.2 (5340) 46.9 (2582) 26.3 (5891)
Comorbidities
Asthma 19.1 (969) 12.9 (2530) 18.8 (1036) 12.0 (2693)
Congestive cardiac disease 0.4 (20) 0.0 (5) 0.2 (13) 0.0 (5)
Rheumatoid arthritis 1.5 (75) 0.6 (121) 2.2 (123) 0.8 (187)
Systemic lupus erythematosus 0.5 (27) 0.1 (22) 0.6 (35) 0.1 (25)
Renal disease 0.9 (48) 0.2 (35) 1.1 (62) 0.3 (65)
Stroke 0.9 (44) 0.1 (22) 0.9 (50) 0.2 (48)
Chronic obstructive pulmonary disease 0.5 (26) 0.2 (30) 0.6 (32) 0.1 (31)
Coronary vascular disease 1.0 (52) 0.3 (50) 1.5 (82) 0.3 (77)
Coagulation disturbances 0.2 (11) 0.0 (9) 0.2 (13) 0.0 (6)
Varicose veins 2.8 (143) 1.6 (314) 2.7 (151) 1.6 (359)
Hypertension 6.3 (319) 3.6 (698) 6.0 (329) 3.7 (831)
Cancer 6.6 (333) 0.9 (180) 6.6 (363) 0.9 (204)
Inflammatory bowel disease 1.9 (96) 0.6 (118) 1.8 (100) 0.6 (143)
Conditions in previous 6 months
Infection 19.0 (964) 10.4 (2033) 17.2 (948) 9.0 (2026)
Surgery or leg/hip fracture 1.1 (54) 0.1 (16) 0.9 (51) 0.1 (24)
Hospital admission 1.4 (72) 0.2 (48) 4.1 (223) 1.1 (248)
indications for hormonal contraceptive use
Acne 12.6 (638) 11.7 (2307) 9.3 (514) 8.6 (1933)
Menstrual disorders 36.5 (1847) 31.0 (6091) 27.2 (1497) 23.0 (5141)
Hirsutism 2.1 (107) 1.3 (260) 1.4 (75) 1.0 (229)
Polycystic ovary syndrome 3.4 (174) 2.2 (433) 3.1 (170) 2.4 (535)
Contraceptive drug use in previous month
Any hormonal contraceptive 32.6 (1649) 20.3 (3996) 33.4 (1838) 19.7 (4418)
Any oral combined contraceptive 24.9 (1259) 14.4 (2835) 23.8 (1309) 12.6 (2823)
Any oral progestogen only 5.1 (260) 4.4 (866) 5.1 (281) 4.0 (907)
Any non-oral hormonal contraceptive 2.6 (130) 1.5 (295) 4.5 (248) 3.1 (688)
Switch in the last month 1.9 (95) 0.6 (110) 1.9 (103) 0.5 (123)
Data are percentage (no) of cases or controls.
*Assumed as white in analyses.
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In the year before the index date, 30% of cases and 
18% of controls in CPRD had at least one prescription 
for combined oral contraceptives. For QResearch, the 
numbers were 28% of cases and 16% of controls. Prepa-
rations with levonorgestrel seemed to be the most com-
monly prescribed combined oral contraceptives (45% of 
exposed cases, 54% of exposed controls in CPRD; 44%, 
52% in QResearch). Other contraceptive types were 
much less used (all between 7% and 13%). Most users of 
combined oral contraceptives within the previous year 
were current users—that is, exposed in the last 28 days 
(84% of exposed cases, 79% of exposed controls in 
CPRD; 84%, 77% in QResearch; web table 3). Most of the 
current users were exposed for more than 84 days 
(across different permutations of drug type, database, 
and cases and controls, all between 70% and 87%).
For the analyses combining CPRD and QResearch 
results, current use of any combined oral contraceptive 
was associated with a significantly increased VTE risk 
(adjusted odds ratio 2.97, 95% confidence interval 2.78 to 
3.17) compared with no exposure in the last year. The 
risks varied between different types of oral contracep-
tives and resulted in two clear groups: norethisterone, 
levonorgestrel, and norgestimate in one group; and 
desogestrel, gestodene, drospirenone, and cyproterone 
in the other. Current exposure showed that the first group 
had a two and a half times increased VTE risk (levonorge-
strel (2.38, 2.18 to 2.59), norethisterone (2.56, 2.15 to 3.06), 
and norgestimate (2.53, 2.17 to 2.96), and roughly a four 
times increased risk for the second group (desogestrel 
(4.28, 3.66 to 5.01), gestodene (3.64, 3.00 to 4.43), dro-
spirenone (4.12, 3.43 to 4.96), and cyproterone (4.27, 3.57 
to 5.11) all compared to no exposure in the last year 
(table 2 , fig 3, web table 4 for all variables in the model).
In our analysis to facilitate comparison with exist-
ing studies, risks associated with current use of nore-
thisterone and norgestimate did not differ significantly 
from levonorgestrel. However, the risk associated with 
current use of gestodene was 1.5 times higher than 
for levonorgestrel (adjusted odds ratio 1.52, 95% con-
fidence interval 1.24 to 1.87) and about 1.8 times 
higher for desogestrel, drospirenone, and cyproterone 
(table 3).
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Fig 2 | use of different types of oral contraceptives by year 
and database. Data are based on age standardised 
exposure in controls using the uK’s general population
table 2 | Current exposure to combined oral contraceptives compared to non-exposure by database
type of contraceptive
CPrD Qresearch Combined analysis
no of cases/
controls
adjusted odds 
ratio (95% Ci)*
no of cases/
controls
adjusted odds 
ratio (95% Ci)*
Pooled odds 
ratio (95% Ci) P
Total No 5062/19 638 — 5500/22 396 — — —
No use in previous year (reference) — 1.00 — 1.00 1.00 —
Current use
 Norethisterone 96/245 2.30 (1.78 to 2.99) 109/259 2.82 (2.21 to 3.60) 2.56 (2.15 to 3.06) <0.001
 Levonorgestrel 521/1451 2.23 (1.97 to 2.52) 540/1411 2.52 (2.24 to 2.84) 2.38 (2.18 to 2.59) <0.001
 Norgestimate 122/370 1.96 (1.56 to 2.46) 160/352 3.15 (2.56 to 3.89) 2.53 (2.17 to 2.96) <0.001
 Desogestrel 165/228 4.43 (3.54 to 5.55) 163/262 4.15 (3.34 to 5.15) 4.28 (3.66 to 5.01) <0.001
 Gestodene 78/149 3.14 (2.32 to 4.24) 115/182 4.07 (3.14 to 5.26) 3.64 (3.00 to 4.43) <0.001
 Drospirenone 139/200 4.36 (3.39 to 5.60) 102/170 3.86 (2.93 to 5.08) 4.12 (3.43 to 4.96) <0.001
 Cyproterone 138/192 4.13 (3.22 to 5.31) 120/187 4.42 (3.41 to 5.73) 4.27 (3.57 to 5.11) <0.001
Different doses of oestrogen
 Norethisterone 20 µg 44/94 2.94 (2.00 to 4.34) 36/79 2.72 (1.78 to 4.16) 2.84 (2.13 to 3.78) <0.001
 Norethisterone 30/40/50 µg 52/151 1.93 (1.36 to 2.72) 73/180 2.87 (2.14 to 3.84) 2.43 (1.94 to 3.03) <0.001
 Desogestrel 20 µg 57/88 4.43 (3.08 to 6.37) 60/97 3.80 (2.68 to 5.41) 4.10 (3.18 to 5.28) <0.001
 Desogestrel 30/40 µg 108/140 4.42 (3.34 to 5.85) 103/165 4.36 (3.33 to 5.71) 4.39 (3.62 to 5.33) <0.001
 Gestodene 20 µg 17/22 4.70 (2.41 to 9.14) 22/25 5.54 (2.99 to 10.28) 5.13 (3.26 to 8.07) <0.001
 Gestodene 30/40 µg 61/127 2.86 (2.05 to 4.00) 93/157 3.83 (2.89 to 5.08) 3.40 (2.74 to 4.21) <0.001
*Adjusted for body mass index, smoking status, alcohol consumption, ethnic group, chronic and acute conditions, and use of other hormonal contraceptives.
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Analyses of oestrogen dosages were possible only for 
norethisterone, desogestrel, and gestodene (20 µg; 
30-40 µg). Desogestrel was the most commonly pre-
scribed of these three drugs and had slightly higher 
odds ratios for higher doses, whereas norethisterone 
and gestodene had higher odds ratios for lower doses; 
however, none of these differences between doses was 
significant (table 2).
Analysis of the duration for current users showed, 
only for levonorgestrel, a significantly increased risk 
for new users and restarters (that is, short term users) 
compared with long term users (adjusted odds ratios 
3.38 (95% confidence interval 2.86 to 3.99) v 2.16 (1.97 
to 2.38), P<0.001). For other drug types, the results 
were inconsistent, with odds ratios for shorter expo-
sure marginally higher for norethisterone and gesto-
dene, but marginally lower for norgestimate, 
desogestrel, drospirenone, and cyproterone (web 
table 5). Adjusted odds ratios for other confounders, 
including use of other hormonal contraceptives (oral 
progestogen only and non-oral hormonal treatments) 
and associations for our category of past use, are avail-
able in web table 4.
Although previous studies have not shown any con-
founding effect from body mass index,11 we found that 
inclusion of body mass index into the model changed 
odds ratios for drug exposures by percentages ranging 
from 7% to over 10%, with the highest effect for dro-
spirenone (web table 6). Each risk factor, when included 
individually, did not show a major effect on the results 
for drug exposures. But when all combined, the odds 
ratios for drug exposures changed by percentages of 
between 13% and 25% compared with the unadjusted 
values. Adjustment for deprivation information in QRe-
search changed odds ratios for exposures by up to 5%.
additional analyses
When restricted to cases with anticoagulation prescrip-
tions and matched controls, the overall pattern of risks 
was similar to those from the main analysis (table 4), 
although odds ratios were higher for all combined oral 
contraceptive drug types within a wide range of relative 
change. The differences were smaller for norethisterone 
(8% increase in adjusted odds ratio) and levonorgestrel 
(24%), and larger for norgestimate (40%), gestodene 
(78%), desogestrel (46%), drospirenone (48%), and 
cyproterone (40%). However, when tabulated by expo-
sure, the variations shown in proportions of cases with 
anticoagulation prescriptions for different exposure 
groups (web table 7) might reflect some differential 
treatment of patients at initial presentation based on 
known drug risks.
The analysis for idiopathic cases (that is, with no risk 
associated conditions) and matched controls showed 
higher odds ratios for the oral contraceptives in the idio-
pathic analysis than the main analysis (table 4), but 
odds ratios by type of oral contraceptive were similar to 
the main analysis results. The odds ratios for the non-id-
iopathic group were correspondingly smaller (web table 
Norethisterone
  CPRD
  QResearch
Subtotal: P=0.267, I2=18.8%
Levonorgestrel
  CPRD
  QResearch
Subtotal: P=0.166, I2=47.9%
Norgestimate
  CPRD
  QResearch
Subtotal: P=0.003, I2=88.9%
Desogestrel
  CPRD
  QResearch
Subtotal: P=0.676, I2=0%
Gestodene
  CPRD
  QResearch
Subtotal: P=0.198, I2=39.7%
Drospirenone
  CPRD
  QResearch
Subtotal: P=0.519, I2=0%
Cyproterone
  CPRD
  QResearch
Subtotal: P=0.713, I2=0%
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2.56 (2.15 to 3.06)
2.23 (1.97 to 2.52)
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3.15 (2.56 to 3.89)
2.53 (2.17 to 2.96)
4.43 (3.54 to 5.55)
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3.14 (2.32 to 4.24)
4.07 (3.14 to 5.26)
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Fig 3 | adjusted odds ratio for vte in patients currently exposed to combined oral 
contraceptives compared with no use in the last year, by database. Odds ratios and 95% 
confidence intervals are adjusted for body mass index, smoking status, alcohol 
consumption, ethnic group, chronic and acute conditions, and use of other hormonal 
contraceptives
table 3 | adjusted odds ratios for current use of different combined oral contraceptives versus levonorgestrel, by database
Drug name
CPrD Qresearch Combined analysis
adjusted odds ratio (95% Ci)* P adjusted odds ratio (95% Ci)* P adjusted odds ratio (95% Ci)* P
Levonorgestrel 1.00 — 1.00 — 1.00 —
Norethisterone 1.03 (0.78 to 1.36) 0.8 1.12 (0.86 to 1.45) 0.4 1.08 (0.89 to 1.30) 0.4
Norgestimate 0.88 (0.69 to 1.12) 0.3 1.25 (1.00 to 1.57) 0.05 1.06 (0.90 to 1.26) 0.5
Desogestrel 1.99 (1.56 to 2.54) <0.001 1.65 (1.30 to 2.08) <0.001 1.80 (1.52 to 2.13) <0.001
Gestodene 1.41 (1.03 to 1.93) 0.03 1.61 (1.23 to 2.12) <0.001 1.52 (1.24 to 1.87) <0.001
Drospirenone 1.95 (1.50 to 2.55) <0.001 1.53 (1.15 to 2.04) 0.004 1.75 (1.43 to 2.12) <0.001
Cyproterone 1.85 (1.42 to 2.41) <0.001 1.76 (1.34 to 2.31) <0.001 1.80 (1.49 to 2.18) <0.001
*Adjusted for body mass index, smoking status, alcohol consumption, ethnic group, chronic and acute conditions, and use of other hormonal contraceptives.
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8), but not as reliable because fewer non-idiopathic con-
trols were available to match to non-idiopathic cases, 
leading to a reduction of the original matching ratio of 
cases to controls from 1:5 to about 1:1.5.
In the analysis of VTE cases according to age group, 
the proportion of the younger group was small (15-24 
years; 13% in CPRD, 9% in QResearch). Odds ratios 
were lower for this group than for the older group (25-49 
years; table 4), but again the overall pattern of risk 
stayed in line with the main analysis.
Risks for combined oral contraceptives compared with 
levonorgestrel were consistent across all the additional 
analyses (table 5), with no significant differences for nore-
thisterone and norgestimate. Odds ratios for other drugs 
ranged from 1.4 to 2.4 (all significant apart from some 
drugs in the non-idiopathic group and in the younger 
group, which were likely to be due to low numbers).
The results from CPRD and QResearch were similar 
with the exception of those for norgestimate. In the 
CPRD analyses, risks associated with norgestimate use 
were similar to risks for levonorgestrel, whereas in the 
QResearch analyses, risks for norgestimate consis-
tently fell between those for levonorgestrel and desoge-
strel across all analyses. However, the combined 
table 4 | additional analyses for current exposure to combined oral contraceptives compared with non-exposure by database
type of contraceptive
CPrD Qresearch Combined analysis
no of cases/
controls
adjusted odds ratio 
(95% Ci)*
no of cases/
controls
adjusted odds ratio 
(95% Ci)*
Pooled odds ratio 
(95% Ci) P
Women treated with anticoagulants
Total No 2533/9882 — 2956/11 933 — — —
No use in previous year — 1.00 — 1.00 1.00 —
Current use
 Norethisterone 52/131 2.70 (1.88 to 3.87) 57/143 2.82 (2.00 to 3.97) 2.76 (2.16 to 3.54) <0.001
 Levonorgestrel 260/683 2.82 (2.36 to 3.38) 297/739 3.06 (2.59 to 3.61) 2.95 (2.61 to 3.33) <0.001
 Norgestimate 71/181 2.52 (1.84 to 3.46) 99/176 4.68 (3.51 to 6.24) 3.53 (2.86 to 4.37) <0.001
 Desogestrel 113/113 7.37 (5.41 to 10.0) 95/132 5.32 (3.95 to 7.17) 6.23 (5.03 to 7.72) <0.001
 Gestodene 57/61 6.89 (4.56 to 10.4) 82/92 6.20 (4.43 to 8.67) 6.47 (4.98 to 8.39) <0.001
 Drospirenone 94/108 6.03 (4.32 to 8.41) 63/76 6.17 (4.20 to 9.05) 6.09 (4.73 to 7.83) <0.001
 Cyproterone 83/99 5.64 (3.99 to 7.97) 73/95 6.36 (4.45 to 9.08) 5.98 (4.66 to 7.66) <0.001
idiopathic cases/controls
Total No 2630/7632 — 2871/8937 — — —
No use in previous year — 1.00 — 1.00 1.00 —
Current use
 Norethisterone 57/96 2.55 (1.78 to 3.66) 74/117 3.08 (2.24 to 4.24) 2.84 (2.23 to 3.60) <0.001
 Levonorgestrel 321/555 2.70 (2.28 to 3.19) 333/602 2.89 (2.46 to 3.39) 2.80 (2.49 to 3.14) <0.001
 Norgestimate 72/163 1.94 (1.43 to 2.64) 104/148 3.64 (2.74 to 4.82) 2.73 (2.22 to 3.36) <0.001
 Desogestrel 107/100 5.09 (3.75 to 6.91) 98/105 4.73 (3.50 to 6.39) 4.90 (3.95 to 6.08) <0.001
 Gestodene 52/68 3.42 (2.28 to 5.12) 66/72 4.58 (3.20 to 6.58) 4.02 (3.07 to 5.27) <0.001
 Drospirenone 86/78 4.91 (3.44 to 7.01) 68/57 5.61 (3.79 to 8.32) 5.22 (4.01 to 6.79) <0.001
 Cyproterone 83/83 4.77 (3.39 to 6.71) 66/79 4.59 (3.19 to 6.61) 4.69 (3.65 to 6.01) <0.001
Women aged 15-24 years
Total No 636/2496 — 493/2135 — — —
No use in previous year — 1.00 — 1.00 1.00 —
Current use
 Norethisterone 15/61 1.10 (0.57 to 2.10) 16/39 3.83 (1.94 to 7.57) 1.99 (1.24 to 3.18) 0.004
 Levonorgestrel 150/431 2.42 (1.87 to 3.13) 88/314 2.28 (1.66 to 3.13) 2.36 (1.93 to 2.89) <0.001
 Norgestimate 31/88 2.25 (1.40 to 3.61) 36/76 4.83 (2.97 to 7.84) 3.26 (2.32 to 4.58) <0.001
 Desogestrel 30/49 4.37 (2.57 to 7.44) 24/49 3.52 (1.97 to 6.29) 3.96 (2.67 to 5.86) <0.001
 Gestodene 11/24 2.56 (1.14 to 5.73) 13/25 4.67 (2.21 to 9.88) 3.53 (2.04 to 6.12) <0.001
 Drospirenone 38/64 3.90 (2.37 to 6.40) 17/49 2.69 (1.40 to 5.17) 3.41 (2.29 to 5.05) <0.001
 Cyproterone 37/63 3.77 (2.34 to 6.07) 31/51 4.95 (2.79 to 8.78) 4.21 (2.92 to 6.08) <0.001
Women aged 25-49 years
Total No 4426/17142 — 5007/20 261 — — —
No use in previous year — 1.00 — 1.00 1.00 —
Current use
 Norethisterone 81/184 2.75 (2.06 to 3.67) 93/220 2.73 (2.10 to 3.56) 2.74 (2.26 to 3.33) <0.001
 Levonorgestrel 371/1020 2.16 (1.87 to 2.49) 452/1097 2.63 (2.31 to 3.00) 2.40 (2.18 to 2.65) <0.001
 Norgestimate 91/282 1.93 (1.49 to 2.51) 124/276 2.92 (2.31 to 3.70) 2.43 (2.04 to 2.89) <0.001
 Desogestrel 135/179 4.62 (3.59 to 5.93) 139/213 4.26 (3.37 to 5.40) 4.43 (3.73 to 5.26) <0.001
 Gestodene 67/125 3.30 (2.38 to 4.57) 102/157 4.03 (3.06 to 5.30) 3.71 (3.00 to 4.58) <0.001
 Drospirenone 101/136 4.75 (3.53 to 6.38) 85/121 4.37 (3.21 to 5.95) 4.56 (3.69 to 5.65) <0.001
 Cyproterone 101/129 4.41 (3.28 to 5.93) 89/136 4.31 (3.20 to 5.80) 4.36 (3.53 to 5.38) <0.001
*Adjusted for body mass index, smoking status, alcohol consumption, ethnic group, chronic and acute conditions, and use of other hormonal contraceptives.
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results, which gave more precise estimates, placed 
norgestimate in the group with levonorgestrel and 
norethisterone. An additional analysis for QResearch, 
which included adjustment for the Townsend depriva-
tion score, showed results similar to the main analysis 
(web table 9).
sensitivity analyses
When combining the results from the databases we dis-
covered significant heterogeneity only for current use of 
norgestimate (I2=89%, P=0.003). The direction of the 
effect was the same in both databases and, after we 
applied a random effect model to combine the results, 
the estimate for norgestimate did not change our con-
clusion of its association being close to the estimates for 
the group of earlier contraceptives (combined odds 
ratio 2.49, 95% confidence interval 1.56 to 3.97).
The sensitivity analysis for QResearch cases identi-
fied only through general practice medical records and 
matched controls delivered results in line with the main 
analysis (web table 10). The sensitivity analysis for 
CPRD practices linked to hospital admission and ONS 
mortality data was based on 346 general practices and 
covered the period between 1 January 2001 and 30 
March 2012. The crude incidence of VTE per 10 000 
women years in this cohort was 5.7 (95% confidence 
interval 5.5 to 5.8). We identified 436 extra cases from 
hospital admission data and 14 from ONS mortality data 
with at least one year of medical records. After exclu-
sions, 2989 cases were included in the analysis, of 
which 2654 (89%) were identified from general practice 
records, 324 (11%) from hospital admission data, and 11 
(0.4%) from ONS mortality data. The results were also in 
line with the main analysis (web table 11).
numbers needed to harm and excess risk
Because combined oral contraceptive use was associ-
ated with increased VTE risk, additional cases of VTE 
would be expected across all types of combined oral 
contraceptives in exposed women compared with unex-
posed women, and particularly in those aged 25-49 
years (table 6). The lowest numbers of extra cases of 
VTE per year per 10 000 treated women were six extra 
cases for levonorgestrel (6, 95% confidence interval 5 
to 7) and norgestimate (6, 5 to 8) for women aged 15-49 
years, and seven extra cases for levonorgestrel (7, 6 to 8) 
table 5 | additional analyses for current use of different combined oral contraceptives compared with levonorgestrel by 
database
Drug name
CPrD Qresearch Combined analysis
adjusted odds ratio 
(95% Ci)* P
adjusted odds ratio 
(95% Ci)* P
adjusted odds ratio 
(95% Ci)* P
Cases with anticoagulant prescription and matched controls
Levonorgestrel 1.00 — 1.00 — 1.00 —
Norethisterone 0.96 (0.65 to 1.41) 0.8 0.92 (0.64 to 1.33) 0.7 0.94 (0.72 to 1.22) 0.6
Norgestimate 0.89 (0.64 to 1.26) 0.5 1.53 (1.12 to 2.09) 0.007 1.20 (0.95 to 1.51) 0.1
Desogestrel 2.61 (1.87 to 3.65) <0.001 1.74 (1.26 to 2.41) <0.001 2.11 (1.68 to 2.67) <0.001
Gestodene 2.44 (1.58 to 3.77) <0.001 2.03 (1.42 to 2.90) <0.001 2.19 (1.66 to 2.88) <0.001
Drospirenone 2.14 (1.49 to 3.06) <0.001 2.02 (1.35 to 3.01) <0.001 2.08 (1.59 to 2.72) <0.001
Cyproterone 2.00 (1.38 to 2.89) <0.001 2.08 (1.43 to 3.03) <0.001 2.04 (1.57 to 2.65) <0.001
idiopathic cases and controls
Levonorgestrel 1.00 — 1.00 — 1.00 —
Norethisterone 0.94 (0.64 to 1.39) 0.8 1.07 (0.76 to 1.50) 0.7 1.01 (0.78 to 1.30) 0.9
Norgestimate 0.72 (0.52 to 1.00) 0.05 1.26 (0.93 to 1.71) 0.1 0.97 (0.78 to 1.22) 0.8
Desogestrel 1.88 (1.35 to 2.62) <0.001 1.64 (1.19 to 2.26) 0.003 1.75 (1.39 to 2.21) <0.001
Gestodene 1.27 (0.83 to 1.94) 0.3 1.59 (1.09 to 2.33) 0.02 1.44 (1.08 to 1.91) 0.01
Drospirenone 1.82 (1.25 to 2.65) 0.002 1.95 (1.29 to 2.94) 0.002 1.88 (1.42 to 2.48) <0.001
Cyproterone 1.77 (1.23 to 2.53) 0.002 1.59 (1.09 to 2.33) 0.02 1.68 (1.29 to 2.19) <0.001
Women aged 15-24 years
Levonorgestrel 1.00 — 1.00 — 1.00 —
Norethisterone 0.45 (0.23 to 0.89) 0.02 1.68 (0.83 to 3.38) 0.1 0.85 (0.52 to 1.38) 0.5
Norgestimate 0.93 (0.57 to 1.52) 0.8 2.12 (1.27 to 3.54) 0.004 1.38 (0.97 to 1.97) 0.08
Desogestrel 1.81 (1.05 to 3.12) 0.03 1.54 (0.85 to 2.81) 0.2 1.68 (1.12 to 2.52) 0.01
Gestodene 1.06 (0.47 to 2.40) 0.9 2.05 (0.94 to 4.44) 0.07 1.50 (0.85 to 2.63) 0.2
Drospirenone 1.61 (0.96 to 2.70) 0.07 1.18 (0.60 to 2.33) 0.6 1.44 (0.95 to 2.17) 0.08
Cyproterone 1.56 (0.95 to 2.56) 0.08 2.17 (1.19 to 3.96) 0.01 1.78 (1.21 to 2.62) 0.003
Women aged 25-49 years
Levonorgestrel 1.00 — 1.00 — 1.00 —
Norethisterone 1.27 (0.93 to 1.74) 0.1 1.04 (0.78 to 1.38) 0.8 1.14 (0.92 to 1.40) 0.2
Norgestimate 0.89 (0.67 to 1.19) 0.4 1.11 (0.86 to 1.44) 0.4 1.01 (0.83 to 1.22) 0.9
Desogestrel 2.14 (1.62 to 2.82) <0.001 1.62 (1.25 to 2.10) <0.001 1.84 (1.53 to 2.23) <0.001
Gestodene 1.53 (1.08 to 2.16) 0.02 1.53 (1.14 to 2.05) 0.004 1.53 (1.22 to 1.91) <0.001
Drospirenone 2.20 (1.60 to 3.02) <0.001 1.66 (1.20 to 2.30) 0.002 1.92 (1.53 to 2.41) <0.001
Cyproterone 2.04 (1.49 to 2.80) <0.001 1.64 (1.20 to 2.24) 0.002 1.83 (1.46 to 2.28) <0.001
*Adjusted for body mass index, smoking status, alcohol consumption, ethnic group, chronic and acute conditions, and use of other hormonal 
contraceptives.
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and norgestimate (7, 5 to 9) for those aged 25-49 years. 
The highest numbers of extra cases of VTE per year per 
10 000 treated women were for desogestrel (14 extra 
cases, 11 to 17) and cyproterone (14, 11 to 17) for ages 
15-49 years, and for drospirenone (17, 13 to 23), desoges-
trel (17, 13 to 21), and cyproterone (17, 12 to 22) for ages 
25-49 years.
discussion
In this observational study based on two large primary 
care databases, women exposed to drospirenone, gesto-
dene, cyproterone, and desogestrel within the last 28 days 
had around a four times increased risk of VTE. Women 
exposed to levonorgestrel, norethisterone, and norgesti-
mate had about two and a half times increase in VTE risk 
compared with women not exposed in the past year. Risks 
for current use of gestodene, drospirenone, cyproterone, 
and desogestrel were 1.5-1.8 times higher than for levo-
norgestrel. Results from the additional analyses stayed in 
line with the main findings, although there were stronger 
associations in the analyses restricted to cases with anti-
coagulant prescriptions and matched controls. These dif-
ferences were expected and can be explained by our 
methodological approach. We saw no significant associa-
tion in the analyses of oestrogen dosages.
strengths and limitations of the study
The main strengths of this study are its recency, com-
prehensiveness, and generalisability. It was based on 
the general female population in the UK aged 15-49 
years, and explored exposure to combined oral contra-
ceptives commonly prescribed during the past 13 years. 
The study also benefitted from the statistical power of 
large samples from the two largest UK primary care 
databases. Consistency in records for diagnoses, life-
style information, and prescriptions allowed us to com-
bine the results from both databases and achieve 
narrower confidence intervals for our estimates. The 
study also benefitted from a consistent design. 
Results were adjusted for several confounding factors 
such as body mass index, smoking status, alcohol use, 
and social deprivation, which were not available to 
some previous studies. Education and family history 
might also be considered to be confounders but neither 
could be included in the analysis because they are not 
recorded sufficiently often on either the QResearch or 
CPRD databases. Because the exposure was based on 
systematically recorded prescription information, the 
study was free from recall bias. All eligible women were 
included, thus eliminating selection bias. Several addi-
tional analyses looking at conflicting methodological 
issues from previous studies allow readers to compare 
and assess the validity of the results.
A study limitation was the potential misclassification 
of exposure to combined oral contraceptives. According 
to the Contraception and Sexual Health survey in Great 
Britain (2000-09), between 25% and 28% of women 
used an oral contraceptive depending on the year.36  Our 
data for both databases had similar age standardised 
rates of exposure to any oral contraceptive—26% for 
QResearch and 29% for CPRD. Because exposure infor-
mation is based on prescriptions, however, there is a 
degree of uncertainty about actual use—when a woman 
started taking the drug or whether she took it at all. 
According to one survey from the United States, 19% of 
women discontinued using oral contraceptives within 
the first six months, more commonly younger women.37 
Because outcome information was collected prospec-
tively, however, we do not see any reason why this effect 
should differ between cases and controls. Such misclas-
sification of exposure might, however, shift odds ratios 
towards unity. Some uncertainty also relates to women 
who may have delayed use of drugs from past prescrip-
tions (and so were actually current rather than past 
users), and to unaccounted residual risk associated 
with women who ceased use for any reason just before 
the current use period. However, these two potential 
misclassifications are likely to be small.
NHS community contraceptive clinics are also a source 
of oral contraceptive pills apart from general practice 
doctors. According to NHS Contraceptive Services reports 
issued between 2005 and 2013 (www.hscic.gov.uk), on 
average 6.9% of women under 25 years old and 1.6% of 
older women received oral contraceptive pills from con-
traceptive clinics. One report in 2005 released the num-
bers separately for combined and progestogen only pills, 
showing that the proportion of combined contraceptives 
prescribed was 91% of all oral contraceptives for younger 
women and 73% for older women.38 From these figures, 
we estimated that in the population, 6.3% of younger and 
1.2% of older women had exposure to combined oral con-
traceptives without related general practice records. 
These women would appear in our analyses as not 
exposed, creating a potential underestimation that might 
table 6 | numbers needed to harm and excess cases per 10 000 patients for different combined oral contraceptives 
prescribed over one year
use in previous year
numbers needed to harm over 1 year (95% Ci) extra cases per 10 000 treated  per year (95% Ci)
all ages (15-49 years)* age 25-49 years† all ages (15-49 years)* age 25-49 years†
Norethisterone 1529 (1159 to 2086) 1169 (874 to 1620) 7 (5 to 9) 9 (6 to 11)
Levonorgestrel 1739 (1506 to 2028) 1452 (1237 to 1723) 6 (5 to 7) 7 (6 to 8)
Norgestimate 1561 (1223 to 2044) 1428 (1077 to 1966) 6 (5 to 8) 7 (5 to 9)
Desogestrel 729 (597 to 899) 594 (478 to 747) 14 (11 to 17) 17 (13 to 21)
Gestodene 905 (697 to 1198) 752 (570 to 1016) 11 (8 to 14) 13 (10 to 18)
Drospirenone 766 (604 to 986) 572 (438 to 758) 13 (10 to 17) 17 (13 to 23)
Cyproterone 731 (582 to 932) 606 (465 to 804) 14 (11 to 17) 17 (12 to 22)
*Based on combined adjusted odds ratios in table 2.
†Based on combined adjusted odds ratios in table 4. 
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shift odds ratios towards unity, with an effect likely to be 
greater in the younger group. 
The additional analyses for younger women did, in 
fact, produce lower odds ratios for all drugs apart from 
levonorgestrel and norgestimate. However, in the direct 
comparisons of different oral contraceptives with levo-
norgestrel, there was no potential bias with respect to 
misclassification of non-users because only oral contra-
ceptive users were involved. Other biases could arise if 
the prescribing regimens of contraceptive clinics differed 
markedly from those of general practices (with one or 
other being more inclined towards higher risk, lower 
priced drugs), or if the material circumstances of women 
attending general practices differed from those attending 
contraceptive clinics. No published data seem to support 
this, however, and we believe that any such effects are 
likely to be negligible especially given the much higher 
proportion of supply from general practices.
There is also some degree of uncertainty in VTE diag-
noses in both CPRD and QResearch practice records, 
because the results of diagnostic tests needed to con-
firm VTE are not generally available on the primary care 
databases. Furthermore, these diagnoses cannot be 
adjudicated in our study as might happen in a clinical 
trial, so may be subject to misclassification bias, with 
some false positives for cases and some false negatives 
for controls. The likelihood of misclassifications is, 
however, much higher for cases than controls because 
of the low incidence of VTE in the general population 
from which the controls are selected—therefore, over-
all, such errors and misclassifications if non-differen-
tial would tend to shift odds ratios towards unity.
Further, the incidence of VTE in our cohorts were 
both within the estimated range of five to 10 cases per 
10 000 person years for young women.39  The slightly 
higher rate within the QResearch cohort can be 
explained partly because the data used in the data-
base’s analysis was augmented by linked mortality 
information from the ONS and hospital episode statis-
tics. This link will have added extra cases to the QRe-
search analysis and reduced diagnostic errors. 
However, the relatively small difference in rates 
between QResearch and CPRD, and the fact that the dif-
ference is also partly explained by the slightly higher 
median age of the QResearch cohort, suggests that nei-
ther analysis has been substantially affected by diag-
nostic errors. An earlier study has also shown that the 
addition of “possible” cases of VTE did not materially 
affect results obtained using only verified cases.40
Patients with a diagnosis of VTE are usually treated 
with anticoagulant medication. In our data, however, 
there are several reasons why VTE cases might not be 
followed by an anticoagulation prescription, such as a 
VTE event resulting in death, or treatment unrecorded 
in the GP record because it was initiated and contin-
ued in a hospital or other community setting. We 
found that, overall, about half of patients with VTE 
had a record of anticoagulation prescription within 
their general practice record. But a more detailed break-
down by exposure and drug type revealed possible dif-
ferential treatment of exposed patients depending on 
contraceptive drug type and roughly reflecting the 
known VTE risks of the drugs.
The higher odds ratios in the additional analysis 
restricted to cases with anticoagulation prescriptions 
than those from the main analysis can be explained by 
a combination of the exclusion of uncertain events and 
differential anticoagulant prescribing by doctors. 
Women who receive anticoagulation treatment, which 
is necessary for VTE, are normally more likely to be true 
cases than those with no treatment recorded. Therefore, 
inclusion of some non-cases in our main analysis prob-
ably shifted odds ratios towards unity. On the other 
hand, our conjecture—based on evidence in our data of 
differential prescribing—is that doctors are more likely 
immediately to prescribe and record anticoagulants for 
patients with VTE symptoms exposed to a high risk oral 
contraceptive drug than for users of lower risk drugs. As 
a result, use of anticoagulation records to exclude 
uncertain events is more problematic in this study, and 
we would argue that results of our restricted analysis 
should be read with caution, indicating little more than 
a general agreement with earlier findings of increased 
odds ratios. In particular, the range of relative increases 
is probably exaggerated and comparisons between drug 
types possibly less reliable.
Finally, the higher odds ratios obtained from the sub-
groups with idiopathic cases and matched idiopathic 
controls, compared with odds ratios from the main 
analysis, were also expected because the absolute risk 
of VTE for unexposed patients is smaller in an idio-
pathic subgroup than that in a non-idiopathic subgroup 
(and by extension a general population).41  Although 
the associations seem to be stronger in the idiopathic 
analysis, we do not believe that they are necessarily 
generalisable because of the wide variation in defini-
tions of idiopathic groups across existing studies, and 
the general difficulties that have been noted in defining 
such groups.42
Comparison with recent studies
In our study, we observed a reduction in prescription 
rates for combined oral contraceptives and an increased 
rate for progestogen only oral contraceptives. This is in 
line with NHS statistics for prescriptions in the commu-
nity, and might reflect the effects of various guidelines 
and recommendations for patients at high risk of VTE.43
Prior to our study, the largest study of VTE and com-
bined oral contraceptives was a cohort study based on 
medical records from the Danish general population, 
covering the period 2001-09 and identifying 4246 
women with a first recorded VTE.12 The Danish study 
adjusted for age, calendar year, and level of education. 
By comparison, our study had more than twice the 
number of VTE cases; added a further four years of 
data; adjusted for body mass index, smoking status, 
alcohol consumption, ethnic group, several chronic 
and acute conditions associated with increased VTE 
risk, and use of other hormonal contraceptives; and 
accounted for age, calendar year, and practice by 
matching. Not all types of combined contraceptives in 
the Danish study were available for comparison, 
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because some are rarely prescribed in the UK. The most 
used contraceptives were levonorgestrel in the UK and 
gestodene in Denmark. In our main analysis, the odds 
ratios for current use of available contraceptives were 
similar to the Danish relative rates. Despite a difference 
in the proportion of cases with anticoagulant prescrip-
tions (52% in our study v 67% in the Danish study), 
results in these subgroups were also similar.
The most recent CPRD based study focused on a com-
parison of VTE risk in idiopathic cases of VTE with anti-
coagulant prescriptions between levonorgestrel and 
drospirenone.14 It was run on records from 2002 to 2009, 
and so was based on fewer practices than in our study. 
For current users, that study showed a threefold increase 
in VTE risk for drospirenone compared with levonorge-
strel (17 v 44 exposed cases; odds ratio 3.3, 95% confi-
dence interval 1.4 to 7.6). In our study, the odds ratios for 
current use of drospirenone were about twice as high as 
for levonorgestrel in our main analysis and all addi-
tional analyses. Another study (2002-08),11  based on 
pharmacological records from a US company and with a 
design similar to the recent CPRD study,14 had more 
women with VTE exposed to drospirenone than levo-
norgestrel (121 v 65). It also showed an increased risk of 
VTE with drospirenone compared with levonorgestrel 
(odds ratio 2.4, 95% confidence interval 1.7 to 3.4). Based 
on the same source of data (the same US company),11 
another study showed a 70% increased risk associated 
with desogestrel (1.7 (1.1 to 2.4)) and no significant 
increase with norgestimate, both compared to levo-
norgestrel.44 All three of these studies differed from ours 
in terms of case inclusion criteria, but their results align 
well with those from our additional analyses.
An Austrian case-control study (2002-06)45  investi-
gated gestodene-containing and second generation 
oral contraceptives (79 and 83 exposed cases, respec-
tively), identifying cases from referral centres and hos-
pitals and deriving exposure information from 
questionnaires. Odds ratios for contraceptive use (with 
reference to non-users) were two to three times higher 
than in our study. But, as the authors suggested, this 
increased risk might be due to what they termed as 
“hospital bias,” which can lead to overestimation of 
VTE risks.46 The study also compared gestodene with 
second generation pills but did not show any significant 
difference between the drugs in several sensitivity anal-
yses. The relative differences between levonorgestrel 
and gestodene seen in our main and additional analysis 
for idiopathic cases were within the confidence interval 
or close to the upper confidence levels of this study.
A Dutch study (1999-2004)9  analysed all available 
oral contraceptives, identifying women with VTE from 
anticoagulation clinics and assessing exposure from 
postal questionnaires and interviews. Most controls 
were, however, acquired by random digit dialling, a 
technique that might have led to selective recruitment 
of a less active group with a poorer health profile than 
the general population.47 This technique and the higher 
response rates in women with VTE than in those con-
trols (79% v 64%) might have introduced a selection 
bias and inflated odds ratios. In fact, the study did 
report higher odds ratios that those more generally 
reported elsewhere and consistently higher odds ratios 
with reference to non-use than our study, although rel-
ative differences with reference to levonorgestrel were 
again close to our findings.
An Israeli cohort study48 (2002-08) compared VTE 
risks for drospirenone with those for second and third 
generation oral contraceptives and found significant 
differences for drospirenone compared with both gener-
ations (rate ratio 1.65 (95% confidence interval 1.02 to 
2.65), 1.43 (1.15 to 1.78), respectively). The pattern of pre-
scribing in this study was different from ours, with most 
common exposure to third generation drugs (384 
exposed cases) and a lower use of levonorgestrel (23 
exposed cases). Our study showed a similar association 
for current use of drospirenone compared with levo-
norgestrel (odds ratio of 1.75), but found no difference 
between drospirenone and third generation drugs.
Despite being a third generation drug, norgestimate 
(282 exposed cases) had associations with VTE risk sim-
ilar to levonorgestrel in our study. But because norgesti-
mate partly metabolises to levonorgestrel,49  its 
classification as a third generation drug is not clearly 
established. A Danish review classified norgestimate as 
a second generation drug and recommended prescrib-
ing it as a first choice contraceptive along with levo-
norgestrel and norethisterone.50  Norgestimate has a 
lower androgenic effect than levonorgestrel and had 
been used at a similar level to levonorgestrel in the Den-
mark study,12  although in our study levonorgestrel was 
prescribed three times more often than norgestimate. 
No significant difference between norgestimate and 
levonorgestrel was shown in the Danish study12  (165 
exposed cases, rate ratio 1.18 (95% confidence interval 
0.86 to 1.62)) or in the US study44 (124, odds ratio 1.1 
(95% confidence interval 0.8 to 1.5)). 
A meta-analysis16  including the Danish and US stud-
ies also demonstrated this non-difference between norg-
estimate and levonorgestrel, although it was not 
highlighted in the main study findings, which focused 
on different drug generations and oestrogen dosages. 
Although norgestimate had been on the market from 
1995, other studies either did not consider norgestimate 
or were underpowered (for norgestimate, only five 
exposed cases in the Dutch study,9  15 in the CPRD 
study,4  and an unclear number in a German study with 
lower total numbers13).
Our study showed no associations between VTE risk 
and oestrogen dose for the three types of combined 
contraceptives, where this could be assessed. Levo-
norgestrel in the UK was prescribed mostly with a 
30-40 µg dose of oestrogen, so oestrogen dose analysis 
was not possible. Comparable preparations for nore-
thisterone have not been analysed before, so direct 
comparison of our results with other studies is not pos-
sible. A lower dose of oestrogen for desogestrel prepa-
rations was associated with a slightly lower risk of VTE, 
which was consistent with existing literature,12  16 but 
our difference was not significant. For combinations 
with gestodene, the numbers of current users were 
insufficient to draw any meaningful conclusions.
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Conclusion
This study, based on two large primary care databases, 
investigated risks of VTE associated with combined 
oral contraceptives prescribed to the general female 
population in the UK. We believe this study has the 
statistical power and sufficient adjustment for relevant 
confounders to be regarded as an important clarifying 
study, which has produced the most reliable possible 
risk estimates using currently available UK prescrip-
tion data. It has confirmed results from other recent 
large scale studies and added new evidence, particu-
larly for newer or less used combined oral prepara-
tions, such as those containing drospirenone or 
norgestimate. Risks associated with combined oral 
contraceptives were, apart from norgestimate, higher 
for newer drug preparations than for second genera-
tion drugs.
The results from our study and the Danish study12 
provide evidence for relevant authorities concerned 
with prescribing guidelines or those involved with reg-
ulation of safety of medicines. In particular, along with 
the Danish study and a US study,44 our results confirm 
the similarity of risks for levonorgestrel and norgesti-
mate in a UK context.
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